<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3640">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354015</url>
  </required_header>
  <id_info>
    <org_study_id>1-Fonseca</org_study_id>
    <nct_id>NCT01354015</nct_id>
  </id_info>
  <brief_title>Diabetes Remote Care Management System</brief_title>
  <acronym>DRMS</acronym>
  <official_title>Diabetes Remote Care Management System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DRMS is a system that communicates with patients via text message using cellphones,
      computers and other devices. It reminds patients about multiple health care and disease
      related issues such as to test their blood sugars and send the result back to the system via
      text message. The system will then decided based on automated algorithms whether to send
      another message advising patients on changing their medication etc.

      This pilot will enroll 100 injectible insulin dependent patients with uncomplicated Type 1
      and Type 2 diabetes mellitus, using insulin, who will be enrolled to participate in the
      pilot. Patients will be randomized 1:1 to either DRMS or standard care. The patients in the
      DRMS program will undergo interactions with the system using multiple communications
      channels including cell phones, IVR, email, web and SMS messaging. The goals of the
      interactive programs are the following:

        1. Monitor and intervene to remind patients to fill their prescriptions

        2. Monitor and track insulin unit consumption utilization and timing of that dosage

        3. Monitor and intervene when the patient does not use or take their medications as
           prescribed.

        4. Monitor and track insulin unit consumption and timing of that dosage

        5. Ask the patient for their glucose levels and then provide customized information to the
           patients regarding how to modify their medication to achieve the desired glucose level

        6. Deliver automated dose adjustment directions based on the providers instructions

        7. Coordinate personalized educational programs and messages into the automated
           intervention programs

        8. Provide feedback to the patients, including performance and reinforcement to both
           providers and to patients.

        9. Provide feedback to providers on patients performance as well as exception based
           reporting

      The System will manage interventions in an automated fashion. Providers will intervene on an
      exception basis and only when automated interventions have not worked or the protocol
      requires immediate action by the provider. For example, if the glucose exceeds certain
      danger levels, as defined by the provider, a requirement might be to call and notify the
      doctor immediately.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective To determine the feasibility of using cell and phone technology to
      monitor, intervene and manage diabetes in patients using insulin.

      Secondary Objectives:

      1.To determine whether the DRMS system leads to improved glucose control (as measured by
      HgA1cHbA1c) during participation in the pilot

      .2.To determine whether the DRMS system leads to improved management and adherence to
      insulin as well as other diabetic medications .3.To determine whether the DRMS system can be
      used as a cost effective solution for interventions across a broad segment (both demographic
      and economic groups) of the diabetes population.

      This pilot will enroll 100 injectible insulin dependent patients with uncomplicated Type I1
      and Type II2 diabetes mellitus, using insulin, who will be enrolled to participate in the
      pilot. Patients will be randomized 1:1 to either DRMS or standard care. It is anticipated
      that 150 patients will be screened in order to enroll 100 patients in the clinical trial.
      The patients in the DRMS program will undergo interactions with the system using multiple
      communications channels including cell phones, IVR, email, web and SMS messaging. The goals
      of the interactive programs are the following:

        1. Monitor and intervene to remind patients to fill their prescriptions

        2. Monitor and track insulin unit consumption utilization and timing of that dosage

        3. Monitor and intervene when the patient does not use or take their medications as
           prescribed.

        4. Monitor and track insulin unit consumption and timing of that dosage

        5. Ask the patient for their glucose levels and then provide customized information to the
           patients regarding how to modify their medication to achieve the desired glucose level

        6. Deliver automated titration directions based on the providers instructions

        7. Coordinate personalized educational programs and messages into the automated
           intervention programs

        8. Provide feedback to the patients, including performance and reinforcement to both
           providers and to patients.

        9. Provide feedback to providers on patients performance as well as exception based
           reporting

      The System will manage interventions in an automated fashion. Providers will intervene on an
      exception basis and only when automated interventions have not worked or the protocol
      requires immediate action by the provider. For example, if the glucose exceeds certain
      danger levels, as defined by the provider, a requirement might be to call and notify the
      doctor immediately.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in A1c from baseline in intervention and control groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fall in HbA1c Over 3 Months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fall in HbA1c</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Use of messaging system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of DRMS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DRMS</intervention_name>
    <description>USE OF TEXT MESSAGING SYSTEM</description>
    <arm_group_label>Use of messaging system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older.

          2. Able to read and understand the ICF and provide written consent.

          3. Diagnosis of Type 1 or Type 2 diabetes. If Type 1 diabetes, requirement that they be
             on insulin and if Type 2 diabetes, requirement that they be on r insulin.

          4. Recent HbA1c blood test (within the last 30 days).

          5. An HbA1c reading of 7.5% - 9.0%.

          6. Patient must own or have access to cell phone on a daily basis throughout the study
             period, and optionally can have a conventional phone or access to the Internet.

          7. Patient possesses a blood sugar monitor and has access to supplies.

          8. Patient is felt to be able to be compliant with the study.

          9. Patient has no plans to move over the 6 month period of the study.

        Exclusion Criteria:

          1. Have active cancer other than basal cell carcinoma or cervical or breast cancer in
             situ.

          2. In the opinion of the investigator are not suitable for entry into the study.

          3. History of any psychiatric or neurologic condition that might impair the patient's
             ability to understand or to comply with the requirements of the study or to provide
             informed consent

          4. Pregnant or breast-feeding females.

          5. History (within last 6 months) of significant cardiovascular disease unless the
             disease is well-controlled. Significant cardiac diseases includes second/third degree
             heart block; clinically significant ischemic heart disease; QTcF interval &gt; 450 msec
             at screening; poorly controlled hypertension; congestive heart failure of New York
             Heart Association (NYHA) Class II or worse (slight limitation of physical activity;
             comfortable at rest, but ordinary physical activity results in fatigue, palpitation,
             or dyspnea) or uncontrolled cardiac arrhythmias.

          6. History of cerebrovascular accident (CVA) within 6 months prior to randomization or
             that resulted in ongoing neurologic instability.

          7. Active infection or serious underlying medical condition (including any type of
             active seizure disorder within 12 months prior to randomization) that would impair
             the ability of the patient to participate in the trial.

          8. Hypoglycemia Unawareness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivian Fonseca</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>January 12, 2015</lastchanged_date>
  <firstreceived_date>May 6, 2011</firstreceived_date>
  <firstreceived_results_date>December 30, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tulane University School of Medicine</investigator_affiliation>
    <investigator_full_name>Vivian Fonseca</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Technology</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>01/01/12 from diabetes clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Use of Messaging System</title>
          <description>Use of DRMS
DRMS: USE OF TEXT MESSAGING SYSTEM</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Usual Care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Use of Messaging System</title>
          <description>Use of DRMS
DRMS: USE OF TEXT MESSAGING SYSTEM</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Usual Care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
                <measurement group_id="B2" value="48"/>
                <measurement group_id="B3" value="98"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="58.9" spread="10.3"/>
                <measurement group_id="B2" value="59.3" spread="8.7"/>
                <measurement group_id="B3" value="59.1" spread="9.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="59"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>self reported</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="64"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c</title>
        <description>change in A1c from baseline in intervention and control groups</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Use of Messaging System</title>
            <description>Use of DRMS
DRMS: USE OF TEXT MESSAGING SYSTEM</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in HbA1c</title>
            <description>change in A1c from baseline in intervention and control groups</description>
            <units>percentage of Hb</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.25" spread="0.2"/>
                  <measurement group_id="O2" value="-0.4" spread="0.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>All statistical analysis used intent-to-treat methodology and all comparisons used a two-tailed test at the .05 level of significance. Continuous variables are reported as means and standard deviations. W</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.2539</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fall in HbA1c Over 3 Months</title>
        <description>Fall in HbA1c</description>
        <time_frame>3 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Use of Messaging System</title>
            <description>Use of DRMS
DRMS: USE OF TEXT MESSAGING SYSTEM</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Fall in HbA1c Over 3 Months</title>
            <description>Fall in HbA1c</description>
            <units>percentage of total Hb</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.5" spread="0.3"/>
                  <measurement group_id="O2" value="-0.2" spread="0.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Use of Messaging System</title>
          <description>Use of DRMS
DRMS: USE OF TEXT MESSAGING SYSTEM</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Usual Care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Vivian Fonseca</name_or_title>
      <organization>Tulane University</organization>
      <phone>5049884026</phone>
      <email>vfonseca@tulane.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
